2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 852

Targeting Fibroblastoid-like Cells By Drug Loaded Engineered Gold Nanoparticles As a Novel Approach for ILD-SSc Treatment
Abstract Number: 674

Targeting Glandular IL-21-Production in Primary Sjogren′s Syndrome Patients By Immunomodulatory Treatment
Abstract Number: 1109

Targeting IL-8 and CXCR1/2 Abrogates RANKL- and ACPA-Mediated Osteoclastogenesis
Abstract Number: 2791

Targeting Micro-RNAs Derived from Extracellular Vesicles to Inhibit of TLR7 and TLR8 Signaling Suppresses Inflammation in a Novel Human-Mouse Chimeric Model of Systemic Lupus Erythematosus
Abstract Number: 2107

Targeting Mir-155 in Rheumatoid Arthritis B Cells Reduces Antibody Production
Abstract Number: 1033

Targeting Notch-Activated M1 Macrophages Attenuates Joint Tissue Damage in a Mouse Model of Inflammatory Arthritis
Abstract Number: 1881

Targeting Oncostatin M in the Target Tissue: Assessment of in-Vivo Affinity and Target Engagement of an Anti-OSM Monoclonal Antibody By Combining Blood and Skin Blister Fluid Data
Abstract Number: 484

Targeting the BTK-JAK Axis in Preclinical Models of Rat Collagen-Induced Arthritis with GS-4059 in Combination with a JAK Inhibitor
Abstract Number: 460

TAS5315, a Novel Bruton’s Tyrosine Kinase Inhibitor, Demonstrates Anti-Inflammatory Effect in Autoimmune Disease Models
Abstract Number: 1436

TAS8274, a Highly Selective Janus Kinase 3 Inhibitor, Demonstrates Potent Efficacy in an Animal Model of Rheumatoid Arthritis
Abstract Number: 2599

TCZ Improves the Pro-Atherothrombotic Profile of Rheumatoid Arthritis Patients Modulating Endothelial Dysfunction, Netosis and Inflammation
Abstract Number: 577

TCZ Modulates the Production of Ccfdna Derived from RA Synovial Cells
Abstract Number: 439

Temple University Hospital Rheumatology Narcotic Contract
Abstract Number: 903

Temporal Arteritis: Is There Any Correlation Between Ultrasonographic Arterial Wall Involvement and the Inflammatory Cellular Infiltrate at Histological Examination?
Abstract Number: 1530

Temporal Trend of Total Joint Replacement in Rheumatoid Arthritis Patients: A Survival Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].